The genomic landscape of RMS further includes genetic aberrations in FGFR4, IGF1R, PDGFRA, ERBB2/4, MET, MDM2, CDK4, and PIK3CA and BCOR providing targets for molecular therapies for this tumor type [345]. The gene discussed is ERBB2; the disease is neoplasm.